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Basilic vein transposition versus biosynthetic
prosthesis as vascular access for hemodialysis
Massimo Morosetti, MD,a Silvia Cipriani, MD,b Sara Dominijanni, MD,c Giovanni Pisani, MD,a
Daniele Frattarelli, MD,a and Fabrizio Bruno, MD,a Rome, Italy
Background: Vascular access (VA) complications account for a significant number of hospital admissions in dialysis and have
substantial costs. A native arteriovenous fistula (AVF) cannot be successfully obtained in all patients. At our center, we
established an autogenous brachial-basilic AVF (BBAVF) in the upper arm in patients with a failed forearm fistula or with
superficial vessels that were unsuitable for preparing a good site for VA. In most of these patients, we resort to prosthetic
materials for creating a functioningVA as the last strategy. The present study compared the outcomes of BBAVF andAV graft
(AVG) in patients undergoing long-term hemodialysis in whom there was no other possibility of creating a VA.
Methods:We analyzed 57 complex patients, 27 randomized to receive AVG and 30 randomized to BBAVF, between 2002
and 2008. TheOmniflow II Vascular Prosthesis (Bio Nova International Pty Ltd, NorthMelbourne, VIC, Australia), the
latest-generation collagen-polyester composite, was used to create the prosthetic VA. Primary patency (PP) and secondary
patency (SP) rates were calculated using the Kaplan-Meier test. The log-rank test was used to compare PP and SP rates
of the single VA.
Results: Length of hospital admission time, total intervention time, andmean interval to the first venipuncture for dialysis
were longer for BBAVF. In the early postoperative period, patients who received BBAVF had a complication rate similar
to those who received AVG; however, patients who received AVG showed a higher rate of long-term adverse events. PP
and SP rates were higher for BBAVF than for AVG, although this was not statistically significant for SP.
Conclusions:Our results show that BBAVF should be the first choice in patients with a good life expectancy and who can
rely on an available temporary VA. However, given the shorter time to use, AVG could be an alternative in patients with
compromised clinical conditions and in whom a temporary VA is not reliable, considering that the long-term outcome
may be considered beneficial regardless. ( J Vasc Surg 2011;54:1713-19.)
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hThe preparation andmaintenance of a well-functioning
vascular access (VA) has always been a major concern for
patients and nephrologists after the first dialysis treatment.
VA complications currently account for a significant num-
ber of hospital admissions in dialysis patients, in addition to
incurring substantial costs from long-term dialysis treat-
ment.1,2 Evidence clearly indicates that a native arterio-
venous fistula (AVF) is superior to other methods of access
in patient survival, flow rates, patency, infection rates, ex-
pense, and ease of maintenance.3
According to the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines, radial-cephalic and brachial-
cephalic AVF are the first and second choice for VA,
respectively. If these options are not possible, as in patients
with a failed forearm fistula or with superficial vessels un-
suitable for preparing a good site for a VA, an autogenous
brachial-basilic AVF (BBAVF) in the upper arm may be
considered.4
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doi:10.1016/j.jvs.2011.06.030Unfortunately, an autologous VA cannot be success-
ully obtained in all patients: anatomic reasons (lack of vein
etwork, atherosclerosis of the arteries), especially in dia-
etic patients and in elderly patients,5 or late referral6 may
ead to the necessity of an alternative strategy. Vascular
ccess grafts (VAG) provide a VA in most patients whose
uperficial vein network does not permit the creation of a
ood native AVF. Regardless, synthetic grafts have gener-
lly exhibited lower survival rates and higher complication
ates than native AVF.7 Graft patency is also limited by
ontinuous venipunctures, which deteriorate synthetic ma-
erials and may alter internal VA hemodynamics.8 For these
easons, continuous effort is made to obtain materials that
an improve patency and decrease complications and failure
ates.
Currently, a number of alternative graft materials are
ommercially available: Polytetrafluoroethylene (PTFE)
een modified in many ways by changing pore size9 and
all thickness10 and by adding rings, outer wraps,11 venous
uffs,12 and coating to the luminal surface.13-15 Tapered
nd stretch grafts16 are also available, and new tunnelling
heaths have been developed to reduce complications of
raft insertion.
A new kind of multilayered, self-sealing polyurethane
Vectra, Thoratec, Pleasanton, Calif) is also available. This
aterial provides a suitable VA immediately after implan-
ation and offers the additional advantage of a short time to
emostasis.17
Bioprostheses derived from bovine mesenteric vein,
uch as ProCol (Hancock Jaffe Laboratories Inc, Irvine,
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December 20111714 Morosetti et alCalif) are a valid alternative to PTFE in patients at risk of
thrombotic events.18 They have been reported to show the
longest patency rate compared with other grafts, even in
patients with multiple failed accesses,19 but they are no
longer commercially available.
Cryopreserved human femoral vein grafts have been
introduced into surgical practice. They are “immune-
invisible,” and therefore not thrombogenic, thanks to
the elimination of the native cellular wall component by
antigen-reduction technology and the endothelialization
of the luminal surface by the recipient’s cells. However, this
kind of graft is not indicated in the general dialysis popula-
tion but only in selected cases.20
The Omniflow II Vascular Prosthesis (OVPII; Bio
Nova International Pty Ltd, North Melbourne, VIC, Aus-
tralia) is a collagen-polyester composite that has been suc-
cessfully used for peripheral vascular replacement21 and as
an arteriovenous bridging graft for hemodialysis.22,23 It is a
truly integrated biosynthetic composite of polyester mesh
and ovine connective tissue components.24 OVPII is com-
posed of a polyester net set on a silicon mandrel that is
implanted on the sheep’s back to form a tube of collagen
that is fixed by glutaraldehyde at the moment of removal.
This prosthesis has the advantage of the natural collagen,
deprived of its immunogenicity, and the polyester net pro-
vides increased mechanical resistance to deterioration after
repeated puncturing. It combines the excellent biocompat-
ibility and hemocompatibility of the biologic collagenous
tissue with the strength and durability of the integrated
polyester mesh.
The advantages of OVPII make a difference in de-
manding applications such as hemodialysis access. In fact,
the tissue wall is easily punctured, even for home dialysis
patients, and OVPII allows high-flow dialysis rates to be
easily achieved. The self-sealing properties ensure that he-
mostasis is rapidly obtained after the dialysis session with
minimum pressure, which reduces the risk of thrombosis.
Many clinical studies have demonstrated that OVPII has
excellent long-term performance, with a recorded patency
of 10 years, superior to other commonly used prostheses
and not significantly below that of autologous fistulas.
Furthermore, OVPII demonstrates excellent resistance to
infection in AV access situations.25-27
To date, no clear evidence is available that documents
the type of VA that could be the best choice in complex
patients.
Patients from our center were selected to undergo a
surgical construction of an autologous VA by basilic vein
transposition or to add prosthetic AVG in the case of
previously failed AVF, either radial-cephalic AVF or brachial-
cephalic AVF, exhausted superficial veins, or unsuitable
vessels. This frequently occurs in long-term dialysis pa-
tients, particularly in those affected with diabetes mellitus
or in hypotension-prone patients. This clinical setting is
generally recognized as unfavorable, and using prosthetic
materials may lead to higher complication rates and limited
VA survival. bIn these patients, we used a basilic vein transposition
urgical technique to set up a BBAVF and the OVPII to
reate prosthetic VAG. The aim of the present study was to
ompare the outcomes of BBAVF and AVG in a population
f patients undergoing chronic hemodialysis in whom there
as no other possibility of creating a VA.
ATERIALS AND METHODS
Patients and study design. We analyzed 57 patients
ho received AVG or BBAVF between 2002 and 2008.
fter obtaining written informed consent, patients were
andomized 1:1 into two groups: 27 patients received AVG
group 1), and 30 patients received BBAVF (group 2). The
rst 59 interventions, as well as 49 repeat interventions due
o malfunction, were performed by the same operators
sing the same surgical techniques.
We used the OVPII prosthesis because it combines the
haracteristic of resistance to repeated venipuncture, typical
f synthetic prostheses, due to the Dacron net, and high
iocompatibility, typical of biologic prosthesis, due to the
vine collagen, thus mimicking the features of an ideal
rosthesis. Moreover, published reports show that the out-
ome with OVPII is better than with PTFE grafts,28 so we
hose not to create another arm in the study to perform
uch a comparison.
BBAVF creation. The end-to-side anastomosis tech-
ique was used to create 30 BBAVF by basilic vein trans-
osition. Briefly, a longitudinal incision was made at the
edial side above the elbow, over the basilic vein, which
as localized and dissected. After being prepared, the
asilic vein was dilated by injecting saline while clamping
ownstream. In this way, we always obtained a diameter of
t least 3 mm, which is thus adequate for creating the
ascular anastomosis.
The median cubital nerve was identified and eventually
reed from the basilic vein. The anterior surface of the vein
as marked to avoid rotation. The distal part was transacted
t the elbow and anastomosed end-to-side to the brachial
rtery by a 6-0 polypropylene suture. The anastomosis was
4 mm. The vein was placed in a subcutaneous tunnel
reated within the incision used for harvesting the vein.
ystemic heparinization was not performed. Needle punc-
uring for hemodialysis was not permitted for at least 44
ays.
Graft implantation. Eight loop-shaped grafts and 21
traight grafts (6-mm diameter, 40-cm length, either for
traight and loop-shaped) were implanted as described
ubsequently. We decided to use a loop-shaped rather than
straight graft based on the availability of a vein at the
lbow with a diameter of at least 3 mm. If such a vein was
isposable, we chose the loop-shaped graft, also consider-
ng that this kind of graft makes it possible to subsequently
lace a straight and more proximal graft, if needed, at the
ame limb.
Before the straight graft was placed, the axillary vein
as localized and prepared over vessel loops at the axilla.
he same procedure was performed at the elbow for the
rachial artery. The 40-cm-long biosynthetic prosthesis
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Volume 54, Number 6 Morosetti et al 1715was cut as needed for the specific patient and washed by
heparinized saline, following manufacturer’s instructions.
An end-to-side anastomosis of about 1.5 cm in length was
performed between the graft and the axillary vein by 6-0
polypropylene suture. The vein was advanced through a
subcutaneous tunnel created by a dedicated tunnelling
device. A 6-mm-long end-to-side anastomosis was created
between the graft and brachial artery using a 6-0 polypro-
pylene suture.
The anastomosis length is usually shorter in BBAVF than
inAVGbecause native vessels tend to dilate, thus leading to an
increase in blood flow, whereas the prosthesis is not able to
enlarge. Moreover, given a graft diameter of6mm, it is not
possible to create an anastomosis6 mm. No systemic hepa-
rinization was administered. Needle puncturing for hemodi-
alysis was permitted after 44 to 50 days.
For loop grafts, which were always placed at the fore-
arm, a comitans vein of the brachial artery or the basilic vein
was localized and prepared over vessel loops at the elbow.
For the brachial artery, the same procedure was performed
at the elbow. The biosynthetic prosthesis was washed with
heparinized saline, following manufacturer’s instructions.
Bioprosthesis were cut to shorten the original length as
determined by the patient’s characteristics, and the loop
was placed in the subcutaneous tissues at the distal third of
the forearm. An end-to-side anastomosis of about 1.5 cm in
length was performed between the graft and the vein by a
6-0 polypropylene suture. A dedicated tunnelling device
was used to advance the vein through a subcutaneous
tunnel. A 6-mm-long end-to-side anastomosis was created
between the graft and the brachial artery using a 6-0
polypropylene suture. Needle puncturing for hemodialysis
was permitted after 26 to 28 days.
During the surgical procedure for BBAVF creation or
AVG implantation, antibiotic therapy with ceftazidime (1
g) was administered as a single-dose therapy.
No anticoagulation protocol was applied. Patients who
were receiving antiaggregation drugs continued their ther-
apy, and patients receiving anticoagulation drugs were
shifted to low-molecular-weight heparin.
All operations were performed on an in-patient basis
due to the poor general condition of the patients.
Data and statistical analysis. We compared primary
(PP) and secondary patency (SP) rates of AVG and BBAVF.
PP rate was defined as the interval between a successful
initial procedure and the first reintervention. SP rate was
defined as the total interval between the initial procedure
and the last dialysis treatment before the VAwas considered
lost. PP and SP rates were calculated using Kaplan-Meier
methods. Log-rank test was used to compare PP and SP
rates of the single VA. Statistical analysis was performed
using SPSS 17.0 software (SPSS Inc, Chicago, Ill).
RESULTS
Clinical characteristics, underlying pathologies, and VA
complications of the two groups are summarized in the
Table. Group 1 included 27 patients (mean age, 69  12
years; mean years on dialysis, 12 7 years) who underwent h9 procedures to implant OVPII. Underlying pathologies
o end-stage renal disease (ESRD) included nephroangio-
clerosis in three, autosomal-dominant polycystic kidney
isease (ADPKD) in four, type 2 diabetes mellitus in two,
ithiasis/pyelonephritis in four, malformative pathologies
n four, and ESRD of unknown origin in 10.
Mean total operation time was 91  15 minutes. The
rst needle puncture for hemodialysis was performed
ithin a mean interval of 27  1 days of the intervention.
n extracorporeal blood flow300 mL/min was obtained
n all cases. Mean hospital length of stay was 4 1 days. No
dverse events were observed in the early postoperative
eriod. No patient died 60 days after the intervention.
During the follow-up period, 31 rescue procedures
ere performed for vascular thrombosis. The procedure
onsisted of surgical embolectomy by a No. 4 Fogarty
atheter, without performing any imaging examination, or
y pharmacologic thrombolysis with endovenous uroki-
ase. The mean time to the first episode of thrombosis was
.3  6.2 months after the intervention. Surgical throm-
ectomy by Fogarty technique was done in 13 patients (five
oop prostheses); of whom, eight patients recovered an
dequate AVG blood flow, and the remaining five required
permanent central venous catheter in the internal jugular
ein because there was no other way to provide a VA for
able. Clinical characteristics, underlying pathologies,
nd vascular access complications of the study patients
ariablea
Group 1 Group 2
P(AVG) (BBAVF)
atients, No. 27 30 —
ge, years 69  12 63  18 .149
ale sex 8 (29.6) 14 (46.6) .05
ength of dialysis, year 12  7 5  4 .004
otal interventions 29 30 —
athologies
Nephroangiosclerosis 3 (11.1) 2 (6.6) —
ADPKD 4 (14.8) 4 (13.3) —
Type 2 diabetes mellitus 2 (7.4) 8 (26.6) —
Lithiasis/pyelonephritis 4 (14.8) — —
Malformative pathologies 4 (14.8) 8 (26.6) —
Unknown origin 10 (37.1) 2 (6.6) —
SLE/MPGN — 4 (13.3) —
Multicystic renal disease — 2 (6.6) —
omplications
Vascular thrombosis 31 (114) 12 (40.0) .001
Pseudoaneurysms 2 (6.8) — .173
Stenoses 2 (6.8) 3 (10.0) .124
Infections — — —
iming
Total operation time,
minutes
91  15 105  28 .08
First needle puncture, days 27  1 47  3 .03
Hospital length of stay, days 4  1 5  1 .179
DPKD, Autosomal-dominant polycystic kidney disease; AVG, arterio-
enous graft; BBAVF, brachial-basilic arteriovenous fistula; MPGN, mem-
ranoproliferative glomerulonephritis; SLE, systemic lupus erythematosus.
Continuous variables are expressed as mean standard deviation; categoric
ariables are number (%).emodialysis. Urokinase was used for thrombolysis in 13
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December 20111716 Morosetti et alpatients (three loop prostheses), with the recovery of an
adequate AVG blood flow in nine, and the remaining four
patients required a permanent central venous catheter, as
described above.
After a mean interval of 14.7  3.7 months after a
rescue procedure, a second thrombotic complication devel-
oped in four patients. Two had been treated by surgical
thrombectomy (two loop prostheses) and two by pharma-
cologic thrombectomy (two straight prostheses). This
time, three patients underwent surgical thrombectomy
(two loop, one straight prostheses) and recovered a good
AVG blood flow. A new thrombosis developed in one of
these patients at 10 days after the reintervention, and a new
surgical thrombectomy was successful. The last patient
(straight prosthesis) received pharmacologic treatment;
however, AVG function did not recover, and a central
venous catheter was necessary.
Graft bridging was used to treat two pseudoaneurysms.
Angiographic examinations were performed in two patients
due to elevated venous-side pressure levels detected during
dialysis sessions that showed two vascular stenoses at the
postanastomotic venous site. These two patients were
treated by percutaneous transluminal angioplasty. In two
Fig 1. Primary patency is shown for arteriovenous graft
24 months. The standard error was 10% for BBAVF atpatients with loop prosthesis, who developed thrombosis, a wew surgical procedure was needed, and a new straight
VPII prosthesis was implanted, as described, because it
as impossible to obtain an adequate blood flow elsewhere.
o complications due to VA infections occurred.
Group 2 included 30 patients (mean age, 63  18
ears; mean years on dialysis, 5  4) who underwent 30
rocedures to create a BBAVF by basilic vein transposi-
ion. Underlying pathologies leading to ESRD inclu-
ed nephroangiosclerosis in two, ADPKD in four, type 2
iabetes mellitus in eight, systemic lupus erythemato-
us/membranoproliferative glomerulonephritis in four,
ulticystic renal disease in two, malformative patholo-
ies in eight, and an unknown cause in two.
Mean total operation time was 105 28 minutes. The
rst needle puncture for hemodialysis was performed
ithin a mean interval of 47 3 days after the intervention,
btaining an extracorporeal blood flow 300 mL/min in
ll cases. Mean hospital length of stay was 5 1 days, which
as a little longer than the AVG mean hospital length of
tay, but not statistically significant. No adverse events were
bserved in the early postoperative period. No patient died
n the first 60 days after the intervention.
During the follow-up period, 12 rescue procedures
G) and brachial-basilic arteriovenous fistula (BBAVF) at
days.(AVere performed for vascular thrombosis, as described for
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after the intervention was 8.2  5.4 months. Ten patients
underwent surgical thrombectomy by Fogarty technique
and recovered an adequate BBAVF blood flow. At a mean
interval of 10.5 4.2 months after the rescue procedure, a
second thrombotic complication developed in two pa-
tients. They underwent repeat surgical thrombectomy, re-
covering a good blood flow.
Three vascular stenoses were treated by percutaneous
transluminal angioplasty (two in the same patient). Anas-
tomosis revision was not required. In one patient, an OV-
PII bridging graft was implanted to treat basilic vein steno-
sis, but adequate blood flow was not recovered.
PP rates at 6, 12, and 24 months were 55%, 32%, and
21%, respectively, for AVG vs 86%, 61%, and 60%, respec-
tively, for BBAVF. SP rates at 6, 12, and 24 months were
72%, 52%, and 34%, respectively, for AVG vs 86%, 76%, and
66%, respectively, for BBAVF. During the observational
period, PP in days was a mean 223 48 for AVG vs 455
50 for BBAVF (Fig 1). The log-rank test showed a statisti-
cally significant difference (P .001). In contrast, mean SP
in days was 330  57 in AVG vs 474  49 in BBAVF (Fig
2), a difference that was not statistically significant by the
log-rank test (P  .08).
Overall mortality at 24 months was 28% in group 1 and
Fig 2. Secondary patency is shown for arteriovenous gr
at 24 months. The standard error was 10% in each gro21% in group 2. sISCUSSION
Easy access to the vascular system is vital in patients
ith chronic renal failure who need long-term intermittent
emodialysis.29 The availability of dialysis and long-term
urvival of patients with ESRD has dramatically increased.
atients who require long-term hemodialysis also need
ong-term VA.30 The primary use of autologous AVF is
ecommended by the KDOQI practice guidelines.31 The
rst and second choice for VA are radial-cephalic AVF and
rachial-cephalic AVF, respectively.4 Unfortunately, many
atients are unable to have or maintain a distal upper limb
VF because of inadequate veins or arteries and therefore
equire more proximal access sites.32 BBAVF offers excel-
ent access in difficult cases. An upper arm VA is also often
laced in patients with unsuitable forearm vessels.33
Controversy still exists regarding the choice of the kind
f VA to be performed in secondary and tertiary access
rocedures, when primary fistulas have failed, in patients
ith a longer duration of dialysis, or in those affected with
ome kind of vessel pathology that makes it difficult to set
p and maintain a functional VA, including diabetic pa-
ients and older patients showing arteriosclerotic degener-
tion.34 The gold standard in VA remains the native distal
r proximal fistula, with or without blood vessels transpo-
VG) and brachial-basilic arteriovenous fistula (BBAVF)aft (Aition. The main factors considered for the choice of a
11
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tency time and avoidance of complications such as infec-
tions and pseudoaneurysm formation.21
Our data demonstrate that the difference between hos-
pital length of stay and total intervention time for BBAVF
and AVG was not statistically significant, but the mean
waiting interval to the first venipuncture for dialysis was
longer for BBAVF (P  .03). Implanting an AVG is much
more expensive than creating a BBAVF.
In our experience, the rate of complications for patients
who received BBAVF was similar to those who received
AVG in the early postoperative period, whereas patients
who received AVG showed a higher rate of adverse events
over the long-term. However, PP and SP for BBAVF was
significantly higher, thus demonstrating the superiority of
this kind of VA on functional and practical grounds. The
limited data available in our experience do not allow us to
draw definite conclusions about the difference between the
two kinds of prosthesis configurations.
CONCLUSIONS
From these results, we believe that BBAVF should be
the first choice in patients with a good life expectancy (2
years) and who can rely on an available temporary VA, such
as a central venous catheter. However, given the shorter
time to use, AVG could be an alternative choice in patients
with compromised clinical conditions and in whom a tem-
porary VA is not reliable, considering that the long-term
outcome may be considered beneficial regardless.
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